GPC3 and lymphopenia: Shi and colleagues discussed results from two phase I studies that enrolled 13 patients with advanced HCC treated with GPC3-CAR T cells; preliminary data showed 2 partial responses, 1-year OS rate of 42%, and most common toxicities included pyrexia, lymphopenia, and cytokine release syndrome (89).